---
schema_version: "secwatch.filing_event.v1"
accession: "0001493152-24-024427"
form_type: "8-K"
ticker: "GCTK"
cik: "0001506983"
company_name: "Glucotrack, Inc."
filed_at: "2024-06-20T23:59:59+00:00"
generated_at: "2026-06-01T03:22:09.101846+00:00"
event_type: "leadership"
sentiment: "positive"
materiality_score: 0.55
calibrated_materiality_score: 0.55
confidence: "high"
source: SEC EDGAR
---

# Glucotrack appoints Andy Balo (ex-Dexcom EVP) to board; bylaws amended to lower quorum to one-third

## Summary
- Appointed Andrew K. Balo, former Dexcom EVP of Clinical & Global Access, to board as independent director, effective June 14, 2024.
- Balo brings 22 years at Dexcom, expertise in glucose monitoring regulatory submissions and clinical trials.
- Board also amended bylaws to reduce shareholder quorum requirement from majority to one-third.
- Balo will assist with upcoming human clinical studies for Glucotrack's implantable continuous blood glucose monitor.
- Balo played critical role at Dexcom; his regulatory knowledge expected to aid Glucotrack's CBGM development.

## SEC filing metadata
- accession: 0001493152-24-024427
- form_type: 8-K
- ticker: GCTK
- cik: 0001506983
- company_name: Glucotrack, Inc.
- filed_at: 2024-06-20T23:59:59+00:00
- event_type: leadership
- sentiment: positive
- materiality_score: 0.55
- calibrated_materiality_score: 0.55
- confidence: high
- sec_items: 5.02, 5.03, 7.01, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1506983/000149315224024427/0001493152-24-024427-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1506983/000149315224024427/form8-k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001493152-24-024427
- JSON: https://secwatch.observer/filing/0001493152-24-024427.json
- Plain text: https://secwatch.observer/filing/0001493152-24-024427.txt

## Key facts
- Executive change
  Andrew K. Balo was appointed as independent board member at Glucotrack, Inc..
  - Action: appointed
  - Role: independent board member
  source text: On June 14, 2024, the Board of Directors of Glucotrack, Inc. (the “Company”) appointed Andrew K. Balo to the Board of Directors as an independent board member.
  evidence_url: https://www.sec.gov/Archives/edgar/data/1506983/000149315224024427/0001493152-24-024427-index.htm

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.